1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Chong Kun Dang Pharmaceutical Corp. (001630) - Financial and Strategic SWOT Analysis Review

Chong Kun Dang Pharmaceutical Corp. (001630) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Chong Kun Dang Pharmaceutical Corp. (CKD) is a pharmaceutical company. The company manufactures, distributes, imports and exports prescription drugs, active pharmaceutical ingredients (APIs), over-the-counter (OTC) drugs and other products. Its product portfolio includes vitamins, shampoos, hair colors, aerosols, mat vaporizers and mosquito coils, among others. CKD Pharma focuses on the application of its latest technologies in fermentation and organic synthesis. The company’s central research laboratory undertakes pharmaceutical research, chemical research and new drug development in the areas of oncology, immunology, cardiovascular, metabolic disease, infectious diseases, central nervous system and respiratory diseases, among others. Some of the company’s pipeline products include Camtobell, Duvie, CKD-942, Dilatrend SR and Telminuvo. The company has presence in South Korea, Japan and China, among others. CKD is headquartered in Seoul, Korea.

Chong Kun Dang Pharmaceutical Corp. Key Recent Developments

May 08, 2013: Chong Kun Dang Pharma Receives US Patent For New Hydroxamate Derivatives

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Chong Kun Dang Pharmaceutical Corp. (001630) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Chong Kun Dang Pharmaceutical Corp. - Key Facts 6
Chong Kun Dang Pharmaceutical Corp. - Key Employees 7
Chong Kun Dang Pharmaceutical Corp. - Major Products and Services 8
Chong Kun Dang Pharmaceutical Corp. - Pharmaceutical Pipeline Products Data 10
Chong Kun Dang Pharmaceutical Corp., Pipeline Products by Therapy Area 10
Chong Kun Dang Pharmaceutical Corp., Pipeline Products by Development Phase 11
Chong Kun Dang Pharmaceutical Corp. - History 13
Chong Kun Dang Pharmaceutical Corp. - Company Statement 18
Chong Kun Dang Pharmaceutical Corp. - Locations And Subsidiaries 19
Head Office 19
Other Locations and Subsidiaries 19
Section 2 - Company Analysis 20
Chong Kun Dang Pharmaceutical Corp. - Business Description 20
Chong Kun Dang Pharmaceutical Corp. - Corporate Strategy 21
Chong Kun Dang Pharmaceutical Corp. - SWOT Analysis 22
SWOT Analysis - Overview 22
Chong Kun Dang Pharmaceutical Corp. - Strengths 22
Strength - Presence Across Wide Range of Indications 22
Strength - Research and Development Activities 22
Strength - Strong Affiliate and Partner Base 22
Chong Kun Dang Pharmaceutical Corp. - Weaknesses 23
Weakness - Decline in Core Product Sales 23
Chong Kun Dang Pharmaceutical Corp. - Opportunities 24
Opportunity - Product Pipeline 24
Opportunity - Strategic Initiatives 24
Opportunity - Growing Therapeutic Markets 24
Chong Kun Dang Pharmaceutical Corp. - Threats 25
Threat - Intense Competition 25
Threat - Stringent Government Regulations 25
Threat - Uncertain RandD Outcomes 25
Chong Kun Dang Pharmaceutical Corp. - Key Competitors 26
Section 3 - Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 - Company's Lifesciences Financial Deals and Alliances 33
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 33
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 34
Chong Kun Dang Pharmaceutical Corp., Recent Deals Summary 35
Section 5 - Appendix 36
Methodology 36
Ratio Definitions 36
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables

Chong Kun Dang Pharmaceutical Corp., Key Facts 6
Chong Kun Dang Pharmaceutical Corp., Key Employees 7
Chong Kun Dang Pharmaceutical Corp., Major Products and Services 8
Chong Kun Dang Pharmaceutical Corp., Number of Pipeline Products by Therapy Area 10
Chong Kun Dang Pharmaceutical Corp., Number of Pipeline Products by Development Stage 11
Chong Kun Dang Pharmaceutical Corp., Pipeline Products By Therapy Area and Development Phase 12
Chong Kun Dang Pharmaceutical Corp., History 13
Chong Kun Dang Pharmaceutical Corp., Other Locations 19
Chong Kun Dang Pharmaceutical Corp., Key Competitors 26
Chong Kun Dang Pharmaceutical Corp., Ratios based on current share price 27
Chong Kun Dang Pharmaceutical Corp., Annual Ratios 28
Chong Kun Dang Pharmaceutical Corp., Interim Ratios 31
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 33
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 34
Chong Kun Dang Pharmaceutical Corp., Recent Deals Summary 35
Currency Codes 36
Capital Market Ratios 36
Equity Ratios 37
Profitability Ratios 37
Cost Ratios 38
Liquidity Ratios 38
Leverage Ratios 39
Efficiency Ratios 39

List of Figures

Chong Kun Dang Pharmaceutical Corp., Pipeline Products by Therapy Area 10
Chong Kun Dang Pharmaceutical Corp., Pipeline Products by Development Phase 11
Chong Kun Dang Pharmaceutical Corp., Performance Chart (2009 - 2013) 30
Chong Kun Dang Pharmaceutical Corp., Ratio Charts 32
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 33
Chong Kun Dang Pharmaceutical Corp., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.